

Informationssøgning i systematiske oversigter

*– involvering af informationsspecialister og
udfordringer i den videnskabelige litteratur*

1. november 2023

Andreas Lundh
Center for Evidensbaseret Medicin Odense (CEBMO)
& Cochrane Danmark
OUH og SDU

www.cebmo.dk

 @AndreasLundh2



Udgangspunkt for oplæg

- Mine erfaring som sundhedsvidenskabelig forsker
- Afbrud undervejs med reflekterende spørgsmål til tilhørerne
- Mulighed for kommentarer og spørgsmål undervejs og til sidst

MENU

Forskningsområder

To projekter

Valg af databaser

Udvikling af søgestrategi

Involvering af informationsspecialister

Søgning i andre informationskilder

Udfordringer i den videnskabelige litteratur

Forskningsområder

- 50/50 forsker og kliniker (infektionsmedicinere)
- Egne forskningsområder:
 - Interessekonflikter i klinisk forskning
 - Interessekonflikter ved peer review og hos tidsskrifterne
 - Metoder i kliniske forsøg og systematiske oversigter
- Samarbejdsområder (metodekonsulent), fx
 - Medicingennemgange
 - Diagnostik af tuberkulose
 - Brug af SMS i sundhedsvæsenet i Afrika
 - Brug af mavesårsmedicin og risiko for COVID-19



En klinisk oversigt



Cochrane Database of Systematic Reviews

Medication review in hospitalised patients to reduce morbidity and mortality (Review)

Bülow C, Clausen SS, Lundh A, Christensen M



Informationskilder

■ Databaser

- CENTRAL
- MEDLINE
- Embase
- CINAHL


**Cochrane
Highly Sensitive
Search Strategy**

■ Forsøgsregistre

- Clinicaltrials.gov
- WHO register

■ Andre kilder

- Referencelister
- Andre artikler af 1. og sidsteforfatter (MEDLINE)
- Kontakt til eksperter inkl. forfattere til forsøg



Ingen forsøg fundet via andre informationskilder

En meta-oversigt

Peer reviewers' conflicts of interest in biomedical research: a scoping review protocol

Christoffer Bruun Korfitsen^{1,3}, Camilla Hansen Nejstgaard^{1,2}, Asbjørn Hróbjartsson^{1,2},
Isabelle Boutron⁴, Lisa Bero⁵, Andreas Lundh^{1,2,6}



Informationskilder

■ Databaser


- MEDLINE
- Embase
- Cochrane Methodology register
- Google Scholar

■ Grå litteratur

- Preprints
- Databaser over ph.d.-afhandlinger
- Konferenceabstracts

■ Andre kilder

- Web of Science (citationer til inkluderede studier)
- Andre artikler af hovedforfattere (MEDLINE)
- Referencelister



Valg af databaser

Ovid MEDLINE®



Embase®



Udvikling af søgestrategi

- Iterativ proces
- Udgangspunkt i forskningsspørgsmål (PICO)
- Starter typisk med Ovid MEDLINE
- Kombination af tekstord og thesaurus
- Evt. brug af søgefilter for studiedesign
- Identifikation af artikel-guldstandard
 - Hjælp til identifikation af 'keywords'
 - Brug til test af søgestrategi
- Råudkast af søgestrategi
- **Feedback fra informationsspecialist**
- 'Forhandling' om endelig strategi
- Sensitivitet vs præcision
- Oversættelse til andre databaser



[Online learning](#)

[Learning events](#)

[Guides and handbooks](#)

[Trainers' Hub](#)

Chapter 4: Searching for and selecting studies

Involvering af informationsspecialist

- Rådgivning om valg af databaser
- Design af MEDLINE søgestrategi
- Oversættelse af søgestrategi til andre databaser
- Praktisk søgning og levering af datafil
- Praktisk hjælp ift referencehåndtering (fx EndNote og Covidence)
- Peer review



Snak med din nabo

Er du som informationsspecialist involveret i:

- Valg af databaser?
- Udarbejdelse af søgestrategi?
- Valg af andre informationskilder?

Hvis ja, på hvilken måde?

Drøft det kort med din nabo



Søgning i andre informationskilder

REFERENCES


1. Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. *MMWR Morb Mortal Wkly Rep.* 2018;67(36):1001-1006. doi:10.15585/mmwr.mm6736a2
2. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. *Am J Public Health.* 2009;99(2):221-227. doi:10.2105/AJPH.2007.131714
3. Volkow ND, McLellan AT. Opioid abuse in chronic pain. *N Engl J Med.* 2016;374(13):1253-1263. doi:10.1056/NEJMra1507771

 Clarivate
Web of Science™



Kontakt til forfattere og eksperter

Corresponding Author: Jason W. Busse, DC, PhD, Department of Anesthesia, Michael G. DeGroot School of Medicine, McMaster University, HSC-2V9, 1280 Main St W, Hamilton, ON L8S 4K1, Canada (bussejw@mcmaster.ca).



Søgning efter grå litteratur



ProQuest
Dissertations &
Theses Global



Søgning i forsøgsregistre

ClinicalTrials.gov

A service of the U.S. National Institutes of Health



Snak med din nabo

Hvad er din erfaring med andre informationskilder (end databaser):

- Har du selv søgt i nogle?
- Kender du andre end de nævnte?
- Vil du anbefale forskere at anvende ikke-peer reviewede studier (fx fra preprints eller konference abstracts)?


Hvorfor/hvorfor ikke?

Drøft det kort med din nabo



Ufordringer i den videnskabelige litteratur

- rovtidsskrifter, zombieforsøg og paper mills



CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials

Kenneth F. Schulz, PhD, MBA; Douglas G. Altman, DSc; and David Moher, PhD, for the CONSORT Group*

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J Page,¹ Joanne E McKenzie,¹ Patrick M Bossuyt,² Isabelle Boutron,³ Tammy C Hoffmann,⁴ Cynthia D Mulrow,⁵ Larissa Shamseer,⁶ Jennifer M Tetzlaff,⁷ Elie A Akl,⁸ Sue E Brennan,¹ Roger Chou,⁹ Julie Glanville,¹⁰ Jeremy M Grimshaw,¹¹ Asbjørn Hróbjartsson,¹² Manoj M Lalu,¹³ Tianjing Li,¹⁴ Elizabeth W Loder,¹⁵ Evan Mayo-Wilson,¹⁶ Steve McDonald,¹ Luke A McGuinness,¹⁷ Lesley A Stewart,¹⁸ James Thomas,¹⁹ Andrea C Tricco,²⁰ Vivian A Welch,²¹ Penny Whiting,¹⁷ David Moher²²

SPRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

An-Wen Chan,¹ Jennifer M Tetzlaff,² Peter C Gøtzsche,³ Douglas G Altman,⁴ Howard Mann,⁵ Jesse A Berlin,⁶ Kay Dickersin,⁷ Asbjørn Hróbjartsson,³ Kenneth F Schulz,⁸ Wendy R Parulekar,⁹ Karmela Krleža-Jeric,¹⁰ Andreas Laupacis,¹¹ David Moher^{2,10}

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Erik von Elm, Douglas G Altman, Matthias Egger, Stuart J Pocock, Peter C Gøtzsche, Jan P Vandenbroucke, for the STROBE initiative



CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials

Kenneth F. Schulz, PhD, MBA; Douglas G. Altman, DSc; and David Moher, PhD, for the CONSORT Group*

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J Page,¹ Joanne E McKenzie,¹ Patrick M Bossuyt,² Isabelle Boutron,³ Tammy C Hoffmann,⁴ Cynthia D Mulrow,⁵ Larissa Shamseer,⁶ Jennifer M Tetzlaff,⁷ Elie A Akl,⁸ Sue E Brennan,¹ Roger Chou,⁹ Julie Glanville,¹⁰ Jeremy M Grimshaw,¹¹ Asbjørn Hróbjartsson,¹² Manoj M Lalu,¹³ Tianjing Li,¹⁴ Elizabeth W Loder,¹⁵ Evan Mayo-Wilson,¹⁶ Steve McDonald,¹ Luke A McGuinness,¹⁷ Lesley A Stewart,¹⁸ James Thomas,¹⁹ Andrea C Tricco,²⁰ Vivian A Welch,²¹ Penny Whiting,¹⁷ David Moher²²

SPRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

An-Wen Chan,¹ Jennifer M Tetzlaff,² Peter C Gøtzsche,³ Douglas G Altman,⁴ Howard Mann,⁵ Jesse A Berlin,⁶ Kay Dickersin,⁷ Asbjørn Hróbjartsson,³ Kenneth F Schulz,⁸ Wendy R Parulekar,⁹ Karmela Krlježa-Jeric,¹⁰ Andreas Laupacis,¹¹ David Moher^{2,10}



The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Erik von Elm, Douglas G Altman, Matthias Egger, Stuart J Pocock, Peter C Gøtzsche, Jan P Vandenbroucke, for the STROBE initiative

Dear Dr. Lundh Andreas,

Hope this finds you in good health and spirit.

I would be honored to acknowledge your excellence and contributions in the fields of “**Respiratory Medicine and Lung Disease**”, it is a great honor for me to contact with such an eminent personality in this field.

We are sincerely requesting you to support with manuscripts to our journal’s **Upcoming Issue**.

Kindly let us know your feasibility to make a submission this time.

As you know, you can submit your manuscript as an attachment to this email or use our online submission portal:

<https://remedysubmissions.com/jrmlid>

Your kind support and cooperation will be highly helpful for journal growth.

Looking forward to hearing from you soon.

Best Regards,

Francesca Redesdale

Editorial Manager


1603 Capitol Avenue

Suite 413A #2833, Cheyenne

Wyoming 82001

USA

Udviklingen af Open Access tidsskrifter og rovtidsskrifter



Get me off Your Fucking Mailing List

In 2005

David Mazières and Eddie Kohler
New York University
University of California, Los Angeles
<http://www.mailavenger.org/>

Abstract

Get me off your fucking mailing list. Get me off your fucking mailing list.

your fucking mailing list. Get me off your fucking mailing list.



Scholarly Open Access
Critical analysis of scholarly open-access publishing

Home About the Author Disclaimer LIST OF PUBLISHERS

LIST OF STANDALONE JOURNALS Other pages

LIST OF PUBLISHERS

Bealls List:

Potential, possible, or probable predatory scholarly open-access publishers

RECENT POSTS

- When Science Go Bad
- Standalone Jov Worst-Ever Open

Amerikansk bibliotekar Jeffrey Beall
- 'opfandt' begrebet **predatory journals**
- skabte **Beall's list** af potentielle rovtidsskrifter i 2008. Fjernet i 2017 pga trusler om sagsanlæg

Et legitim tidsskrift?



British Journal of Medical and Health Research (BJMHR) is a Monthly International On peer-reviewed research in the Medical, Pharmaceutical and Life sciences field on the basis website for the online publication of research articles, review articles, case studies or short scholars.

British Journal of Medical and Health Research(BJMHR) Scientific Journals were deve at all levels.

July **2023 issue was publi**
Next issue will be published on 25

IBI Factor 'BRITISH JOURNAL OF MEDICAL AND HEALTH RESEARCH' is 2

Editorial Board



Name:Edit
Degree:Po
Address:F
Speciality
Email-Id:S



Rapid publication is hallmark feature of BJMHR. We publish article within a week provided that there is no delay from corresponding author in case of any correction.

There is no charge for the processing of papers but author(s) of each accepted paper is required to pay a publication charge as mentioned below Indian authors 2500 Rs, International authors 100 \$ USD Maximum 4 authors should be allowed. Published papers appear electronically and are freely available from our website.



Snak med din nabo

Hvad er dine erfaringer med rovtidsskrifter:

- Har du stødt på nogle?



Hvis ja, i hvilken sammenhæng?

Drøft det kort med din nabo





Ive
Infe
S




All-cause mortality

Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic


Ahmed Elgazzar (✉ dr_ahmed_elgazzar@yahoo.com)
Banha University
Abdelaziz Eitaweel
Banha University
Shaimaa Abo Youssef
Banha University
Basma Hany
Community Medicine Department, Faculty of Medicine, Beni
Mohy Hafez
Banha Faculty of medicine
Hany Moussa
Kafr Elsheikh University, Faculty of medicine, Chest depart

Article



Engelsk sundhedsvidenskabelig
Buster **Jack Lawrence**
Samarbejdede med andre

Plagiering



Caly et al. [7] revealed that ivermectin hindered extreme intense respiratory syndrome-coronavirus 2 (SARS-CoV-2) in

Fabrikation/falsifikation
Inklusionskriterier 18-80 år (datasæt 3 pt's < 18 år)
Inklusionsperiode 8. juni – 20. september 2020 (størstedelen af døde patienter døde før 8. juni)
1 patient udskrevet 31 juni!
Minimum 79 patienter er 'kloner' af andre patienter




John Carlisle
Redaktør af *Anaesthesia*


False individual patient data and zombie randomised controlled trials submitted to *Anaesthesia*

J. B. Carlisle^{1,2} 

- Analyserede 526 indsendte manuskripter fra 2017-20
- Rådata fra 153 (29%) forsøg



An unsolicited email from a paper mill to an SCI journal editor, and the following exchange (January–April 2022). The editor followed up the contact per email and a recorded Zoom meeting in order to detail the fraudulent business model, including the evidence of corruption.



Paper Mill

We are a well-known academic support institution from Guangzhou, China, which has been established for 8 years. Experts in our institution need to publish some research papers in SCI journals every month. For reducing the publication time, we expect to cooperate with you in the future. Cooperation mode: we cite the content of your journal in our articles, thus increasing ... your impact factor in 2022. You shall help us shorten the publication time. Payment: If an article is successfully published, we will pay for it at the price: $IF * 1000 \text{ USD/article}$. For example, with $IF=2.36$, total payment= $2.36 * 1000 \text{ USD}=2360\text{USD}$. And this price is negotiable.

What you can get:

1. An increased journal impact factor in 2022
2. Desirable payment we give


Systematic fabrication of scientific images revealed

Jana Christopher

FEBS Letters Editorial Office, Heidelberg University Biochemistry Center, Germany

- 12 manuskripter indsendt til FEBS tidsskrifter i 2017-8 fra forskellige forskningsgrupper
- Indeholdt identiske western blots fundet ved tidsskrifternes billed-plagierings software

Manuscript 1 (FEBS Letters):



Manuscript 2 (FEBS Journal):




Exclusive: Russian site says it has brokered authorships for more than 10,000 researchers



- Internationalt forlag LLC
- Forfatterskaber solgt via russisk ebay lignende hjemmeside (123.ru)
- Pris 500-5000 USD/artikel
- Fabrikerede data
- Redaktører snydt eller medskyldige
- Primært indenfor naturvidenskab med forfattere fra Rusland og Kina

*Retractionwatch
Abalkina A. Arxiv.org*



Cochranes anbefalinger

As with comments and letters, preprints (versions of scientific articles that precede formal peer review and publication in a journal) should also be considered a potentially relevant source of study evidence. Recent and

Anvend preprints


If there are questions about the trustworthiness of an included study (or one that is eligible for inclusion) in a Cochrane Review, steps should be taken to ensure that the study is acceptable for inclusion. Recommended steps for this are detailed in the **Implementation Guidance** [↗](#). Any concerns about a study must be resolved before the study data can be included in a Cochrane Review.

**Udelad
zombieforsøg**

**Ingen direkte politik
ift rovtidsskrifter**


Konklusion

- Udarbejdelse af systematiske oversigter kræver viden om mange typer af informationskilder
- Informationsspecialister er en vigtig samarbejdspartner for forskeren i mange led i litteratursøgningsprocessen
- Samarbejdet optimeres ved god dialog og plan for rollefordeling og arbejdsopgaver
- Forskningslitteraturen er udfordret af kommercielle interessenter fx rovtidsskrifter og paper mills
- Problematiske studier som zombieforsøg udfordrer den videnskabelige litteratur



Hvordan spotter du et zombieforsøg?

- Forfattere med tidligere retractions
- Få forfattere med lille forsøgs-/statistisk erfaring
- Sygdomsprævalens og inklusionsperiode er suspekt
- Få patienter udgik af forsøget
- Problemer med forsøgsregistrering og etisk godkendelse
- Baseline data er for 'pæne' (check SD'er)
- Usandsynlige baseline/effektmåls data



Jack Wilkinson
Biostatistician from Manchester